A Randomized, Open-Label, Replicate Treatment, 2-Part, Crossover Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches Manufactured at Different Sites
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Granisetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Kyowa Kirin
- 24 Mar 2022 Status changed from recruiting to completed.
- 07 Sep 2021 New trial record